Arbutus Biopharma Corporation has administered the first dose to a patient in the Supplementary Treatment arm of their Phase 2a triple combination Clinical Trial
Arbutus Biopharma Corporation (Nasdaq: ABUS), a biopharmaceutical company in the clinical stage, known for its profound virology knowledge and dedication to developing innovative therapeutics targeting specific viral diseases, has recently disclosed the dosing of the first patient in the expanded treatment arm of the AB-729 Phase 2a triple combination clinical trial. This trial now includes the addition of nivolumab, a PD-1 monoclonal antibody.
In patients with chronic hepatitis B infection, the goal of the additional treatment arm is to determine whether a low dose of nivolumab, in combination with booster dose(s) of Vaccitech plc’s (Nasdaq: VACC) VTP-300, will further stimulate immune mediated reduction of HBsAg.
The primary objective of AB-729 is to target and decrease all hepatitis B viral proteins and antigens, including the crucial hepatitis B surface antigen, in order to facilitate the reactivation of the patient’s immune system and enhance its response to the virus. In the expanded Phase 2a triple combination clinical trial, known as AB-729-202, the safety, antiviral activity, and immunogenicity of nivolumab, along with Vaccitech’s VTP-300, an antigen-specific immunotherapeutic encoding multiple hepatitis B antigens, are being evaluated. This assessment takes place following the administration of AB-729 and ongoing nucleoside analogue (NA) therapy.